Skip to main content


Development pipeline icon


Kala Is Advancing an Innovative Pipeline Based on its Proprietary Mesenchymal Stem Cell Secretome (MSC-S) Platform for the Treatment of Rare Front and Back of the Eye Diseases

Product Candidate* Indication Route of Administration Preclinical Phase 1 Phase 2 Phase 3
KPI-012 for Rare Ocular Surface Disease Persistent Corneal Epithelial Defect (PCED) (Phase 1) Topical
Ocular Manifestations of Moderate-to-Severe Sjögren’s (Preclinical) Topical
Partial Limbal Stem Cell Deficiency (LSCD) (Preclinical) Topical
KPI-014 Program for Rare Inherited Retinal Disease (Preclinical) Intravitreal Injection

*Product candidates are investigational and have not been approved by any regulatory authority.

Please review our Privacy Statement(opens new window). This website uses cookies. By using our website without changing your cookie settings you agree to our use of cookies as described in our Privacy Statement(opens new window) .